December 26, 2014 4:00 PM ET


Company Overview of Inhibiton Therapeutics, Inc.

Company Overview

As of May 5, 2009, Inhibiton Therapeutics, Inc. was acquired by AlumiFuel Power, Inc., in a reverse merger transaction. Inhibition Therapeutics, Inc. engages in the research and development of cancer therapeutic agents and cancer fighting drugs called targeted therapies. The targeted therapies identify molecular causes of cancer and inhibit the signals that cancer cells need to multiply. The company was incorporated in 2000 and is based in Englewood, Colorado.

7315 East Peakview Avenue

Englewood, CO 80111

United States

Founded in 2000



Key Executives for Inhibiton Therapeutics, Inc.

Inhibiton Therapeutics, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
BioDisplay Technologies, Inc. United States
Cold Genesys Inc United States
Attometrics, Inc. United States
Potentia Pharmaceuticals, Inc. United States
EnviroGro Solutions, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Inhibiton Therapeutics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at